Mark your calendars:

May 27 - 28, 2024

Mainz – Germany
Close to Frankfurt Airport

The Neuro4D Conference

Drug Discovery for Proteopathic Neurodegenerative Diseases:
New Insights, Models, & Biomarkers, Novel MoA & Clinical Results

On-site Registration is available
no accommodation included

Major Sponsors:

Conference Topics:

The Neuro4D is a focused and highly interactive international conference on Neuro Degenerative Disease Drug Discovery, bringing together drug discovery companies, service and technology providers, and academic innovators in the field of proteopathic neurodegenerative diseases.

Neuro4D brings a limited number of distinguished industry and academic speakers, poster presenters and delegates in neurodegenerative disease in direct contact, and creates lively discussions about drug discovery efforts for two full days, in a stimulating and enjoyable setting. Academic research leaders outline recent findings and insights into the complex disease mechanisms. Biotech and international pharmaceutical drug companies present their developments for new treatment options and outline advantages and disadvantages of models and technologies used for compound selection and optimization. Service and technology providers present their platforms and show examples of how their services contribute to the discovery of new drug candidates. By the end of the conference, all participants get to know each other, prompting productive collaborations.

In 2024 we will unify our previous and new participants again in the inspiring environment of Mainz, Germany. The conference will stick to the successful session format and chairperson leadership. Each speaker has 15 min for presentation and Q&A, as they decide, and will participate in a podium discussion with all speakers at the end of each session. This year we will focus on Parkinson’s disease, ALS, Huntington’s disease, etc. for our conference on proteopathic neurodegenerative diseases.

Online Registration for 2024 includes conference hotel accommodation from Sunday, May 26 to Tuesday, May 28 for all delegates, food and drinks during the entire two days of the event, joint social activities, and the highly praised interactive conference dinner party on Monday evening.

Please bring your ID for conference registration.

Each registered delegate is entitled and encouraged to show a poster during the conference. The deadline for poster abstract (max. 300 words) submission 2024, is April 14! They will be checked and confirmed ASAP. Accepted abstracts of participating delegates will be published in the program. Please submit your abstracts in MS Word, or as Email text to the organizer:

Poster boards have portrait orientation with a width of 118.5 cm and a height of 146 cm. Posters must have a maximum size of A0 (84 × 119 cm). Poster presenters are requested to be at their posters during dedicated breaks.

The Neuro4D Poster Award: The Neuro4D Poster Award will be awarded to the: ‘Best Results towards Treatment of Neurodegenerative Diseases ‘, presented at the International Neuro4D Conference 2024. It will be selected by all conference participants. At the end of the conference the winner will be presented and awarded with a certificate and 1000 € in cash!

All presentations incl. Q&A will be 15 min. A chairman-led podium discussion of 15 min with all speakers of the past session will follow. Chairmen will introduce their session subject with a 30 min presentation.

Conference Venue:
Atrium Hotel Mainz
Flugplatzstraße 44
55126 Mainz
Tel.: +49 6131 80 15 0
Draft Program:
download 2024 Conference Program (PDF)
last update: April 25, 2024
Topics Highlights:
2023 was the year that finally brought new treatment approvals for Alzheimer’s disease. Antibodies against misfolded amyloid-β aggregates have shown significant preservation of cognition, confirming the crucial role of soluble misfolded protein aggregates in neurodegeneration. In Parkinson’s disease we have finally an FDA-approved biomarker.

The prion-like mechanism plays important roles in many neurodegenerative diseases and possibly even psychiatric disease, as we heard last year. In 2024 we want to hear about the progress that has been made in understanding and treatment of Parkinson’s and Huntington’s disease, ALS, FTD and further ‘amyloid’ diseases.

We will learn the newest results how these aggregates have been detected, quantified and structurally characterized. How disease spreads from neuron to neuron, results in synaptic loss, neuronal dysfunction, brain inflammation and finally brain atrophy.

In the clinical session, we will hear about recent biomarker developments and the most promising drug discovery programs, which we will discuss for clinical observations of side effects, outcomes and benefit for patients and caregivers.
Target Audience:
  • Drug discovery experts from biotech and pharmaceutical industry
  • Academic experts in proteopathic neurodegenerative diseases interested in drug discovery
  • Service providers and users of up-to-date drug discovery technologies, analytical tools, and models of neurodegeneration
  • Pharma strategists and investors interested in the field and prepared to fund the most innovative approaches
  • PhDs looking for new positions in the field
Advisory Committee:

Rakez Kayed, UTMB, Galveston, USA
Neil Cashman, ProMIS, Vancouver, Canada
Oliver Peters, Psychiatric Clinic, Frankfurt-Oder, Germany
Erich Wanker, Max Delbrück Centre, Berlin, Germany
Janine Kutzsche, Research Center Jülich, Germany
Manuel Buttini, U. Luxembourg, Luxembourg
Steffen Rossner, University of Leipzig, Germany

Corporate* Academic*  
1990 € 890 € Regular
(until May 17)
*all registrations include accommodation in the conference hotel from Sun May 26 to Tue May 28 2024, all meals and drinks during the conference, and the conference dinner.
Add. nights in conference hotel: 180 €
On Site Registration: incl. meals and drinks, but excl. accommodation
All prices: plus 19% German VAT, mandatory for events held in Germany
Online Registration including Accommodation ends
May 17, 2024!
Later, or on-site registration (Deadline: May 19, 2024) does not include accommodation.
Dr. Andreas Köpke (bioExpert)
Tel: +49 6136 957 3000